4 February 2020 - To contribute to the global response to the outbreak of the novel coronavirus (2019-nCoV) infections, EMA is taking concrete actions to accelerate the development and availability of medicinal products for the treatment and prevention of the new coronavirus.

"EMA has activated its plan for managing emerging health threats," says Guido Rasi, the Agency's Executive Director. "The new coronavirus has been declared a public health emergency of international concern by the World Health Organization, and we are drawing on the strong expertise of the European medicines network to provide fast-track scientific advice and give prompt feedback on any proposed medicine developments.”

The Agency is surveying the landscape for potential antivirals or vaccines to treat or prevent novel coronavirus infections.

Read EMA press release